Home
Recent press, briefings and insights helping you stay informed on AliveDx newest launch.
hVIVO, based in London, UK, is a world leader in the testing of vaccines and antivirals using human challenge study models. “We are delighted to exclusively partner with Quotient to bring fast and accurate COVID-19 antibody testing to the UK. Open Orphan plc,
The MosaiQ COVID-19 Antibody Microarray is designed as a serological disease screen specific to COVID-19. The assay detects the IgG and IgM antibodies directed at SARS-CoV-2. In addition to the concordance studies, the Company observed seroconversions (the generation of antibodies
JERSEY, Channel Islands, April 27, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported very strong final study performance data for its SARS-CoV-2 antibody test. The Company expects to complete the CE marking process and the
JERSEY, Channel Islands, April 21, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive performance data for its SARS-CoV-2 antibody test. Based on these results, under applicable regulations, the Company can now offer the MosaiQ
JERSEY, Channel Islands, April 06, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-19) antibody test for the fully automated high throughput MosaiQ
JERSEY, Channel Islands, Feb. 14, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has received the Conformité Européene (CE) Mark approval for the Initial Serological Disease Screening (SDS) Microarray. “We are very
“We are very encouraged by these results. The Initial SDS and the Expanded Immunohematology Microarray will be the first powerful commercial combination to hit the market. These results continue to demonstrate the effectiveness of the MosaiQ™ platform,” said Franz Walt, CEO
“The timely submission of our initial SDS microarray is yet another major step for the Company, advancing our efforts to demonstrate the effectiveness of MosaiQ in the transfusion diagnostics marketplace. The next steps include the submission of the initial SDS
Initial IH Microarray Approval in Europe Following the successful conclusion of its first EU field trial in July 2018 and the subsequent submission of the technical dossier for CE Mark approval in late September 2018, on April 30, 2019, the Company was informed that it had
Initial SDS Microarray – Field Trial Assay Performance Field trial results for the initial MosaiQ SDS Microarray used for the detection of CMV and Syphilis achieved the required clinical performance. The field trial data was obtained by donor center testing